AU Patent

AU2013200555A1 — Methods for treating cutaneous lupus using aminoisoindoline compounds

Assigned to Celgene Corp · Expires 2013-02-21 · 13y expired

What this patent protects

Methods of treating cutaneous lupus in a human are disclosed. Specific methods encompass the administration of (+)-2-[-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]4 5 acetylaminoisoindoline-1,3-dione, 4-(amino)-2-(2.6-dioxo(3-piperidyl))-isoindoline-1,3-dione (ACTIMID TM…

USPTO Abstract

Methods of treating cutaneous lupus in a human are disclosed. Specific methods encompass the administration of (+)-2-[-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]4 5 acetylaminoisoindoline-1,3-dione, 4-(amino)-2-(2.6-dioxo(3-piperidyl))-isoindoline-1,3-dione (ACTIMID TM), 3-(4-amino-I-oxo 1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione (REVLIMID*), or cyclopropyl 2-[(1S)-1-(3 ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindolin 4-yl] carboxamide, alone or alternatively, in combination with a second active agent. C: pord\SPEC-832221.docx

Drugs covered by this patent

Patent Metadata

Patent number
AU2013200555A1
Jurisdiction
AU
Classification
—
Expires
2013-02-21
Drug substance claim
No
Drug product claim
No
Assignee
Celgene Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.